How anticoagulants work

Techniques in Regional Anesthesia and Pain Management

Volumn 10, Issue 2, 2006, Pages 30-39

  Jay, Richard M ^a   Lui, Philip ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Anti coagulants; Anti platelets; Anti thrombotics; Duration; Pharmacokinetics; Reversal

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ARGATROBAN; CLOPIDOGREL; DANAPAROID; DESULFATOHIRUDIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHYTOMENADIONE; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD TRANSFUSION; BLOOD VESSEL INJURY; CELL INTERACTION; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG ACETYLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME ACTIVATION; ENZYME INACTIVATION; FIBRINOLYSIS; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; LUNG EMBOLISM; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PLASMA CLEARANCE; PROSTAGLANDIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOCYTE TRANSFUSION; TOTAL HIP PROSTHESIS; URINARY EXCRETION;

EID: 33745727140     PISSN: 1084208X     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.trap.2006.04.002     Document Type: Article

References (58)

1. Warkentin T., and Crowther M. Reversing anticoagulants both old and new. Can J Anaesth 49 suppl (2002) S11-S26
2. Colman R.W. Overview of hemostasis. In: Colman R.W., Hirsh J., Marder V., et al. (Eds). Hemostasis and Thrombosis. ed 4 (2001), Lippincott, Williams and Wilkins, Philadelphia, PA 3-20
3. Leung L. Hemostasis and its regulation. ACP Medicine 5 (2003) 1-10
4. Loscalzo J. Overview of hemostasis and fibrinolysis. In: Sasahara A., and Loscalzo J. (Eds). New Therapeutic Agents in Thrombosis and Thrombolysis. ed 2 (2003), Marcel Decker, New York 1-7
5. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemostas 31 (2005) 174-183
6. Patrono C., Coller B., Fitzgerald G., et al. Platelet-active drugs. the Relationships among dose, effectiveness and side effects. Chest 126 suppl (2004) 234S-264S
7. Hirsh J., O'Donnell M., and Weitz J. New anticoagulants. Blood 105 (2005) 453-463
8. Di Nisio M., Middeldorp S., and Buller H. Direct thrombin inhibitors. N Engl J Med 353 (2005) 1028-1040
9. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 330 (1994) 1287-1294
10. Schroder H., and Schror K. Clinical pharmacology of acetylsalicylic acid. Z Kardiol 81 (1992) 171-175
11. Harder S., Klinkhardt U., and Alvarez J.M. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy. Clin Pharmacokinet 43 (2004) 963-981
12. Product monograph Ticlid, Roche (USA), revision March 2001
13. Buur T., Larsson R., Berglund U., et al. Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J Clin Pharmacol 37 (1997) 108-115
14. Product monograph Plavix, Sanofi-Synthelabo, preparation October 1998, revision April 2004
15. Muller I., Seyfarth M., Rudiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85 (2001) 92-93
16. Weber A.A., Braun M., Hohfeld T., et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacology 52 (2001) 333-336
17. Mascelli M.A., Lance E.T., Damaraju L., et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 97 (1998) 1680-1688
18. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90 (1994) 1757-1764
19. Faulds D., and Sorkin E.M. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischemic heart disease. Drugs 48 (1994) 583-598
20. Product monograph Integrillin, Key Pharmaceuticals (Canada), preparation June 1999, revision June 2004
21. Harrington R.A., Kleiman N.S., Kottke-Marchant K., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 76 (1995) 1222-1227
22. Alton K.B., Kosoglou T., Baker S., et al. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 20 (1998) 307-323
23. Product information, AHFS Drug Information. Aggrastat (tirofiban hydrochloride). Bethesda, MD (USA), 2005
24. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96 (1997) 1445-1453
25. Product monograph Coumadin, Bristol-Myers Squibb (USA), revision April 2005
26. Breckenridge A.M. Oral anticoagulant drugs. pharmacokinetic aspects. Semin Hematol 15 (1978) 19-26
27. Harder S., and Thurmann P. Clinically important drug interactions with anticoagulants. an update. Clin Pharmacokinet 30 (1996) 416-444
28. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists. Chest 126 suppl (2004) 204S-233S
29. Product information, AHFS Drug Information. Heparin sodium. Bethesda, MD (USA), 2005
30. De Swart C.A.M., Nijmeyer B., Roelofs J.M.M., et al. Kinetics of intravenously administered heparin in normal humans. Blood 60 (1982) 1251-1258
31. Kronemann H., Eikelboom B.C., Knot E.A., et al. Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting. J Vasc Surg 14 (1991) 208-214
32. Kleinschmidt K., and Charles R. Pharmacology of low molecular weight heparins. Emerg Med Clin North Am 19 (2001) 1025-1049
33. Product monograph Lovenox, Aventis Pharma (Canada)
34. Product monograph Fragmin, Pfizer (Canada), preparation September 2003, revision September 2004
35. Product monograph Innohep, LEO (Canada)
36. Product monograph Fraxiparine, GlaxoSmithKline (Canada), preparation September 2004, revision October 2004
37. Product monograph Arixtra, GlaxoSmithKline (Canada), preparation May 2002, revision March 2004
38. Donat F., Duret J.P., Santoni A., et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clinical Pharmacokinet 41 suppl 2 (2002) 1-9
39. Koopman M.M.W., and Buller H.R. Short and long acting synthetic pentasaccharides. J Intern Med 254 (2003) 335-342
40. Weitz J.I. New anticoagulants for treatment of venous thromboembolism. Circulation 110 suppl 1 (2004) I19-I26
41. Bradbrook I.D., Magnani H.N., Moelker H.C., et al. ORG 10172. a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 23 (1987) 667-675
42. Ibbostson T., and Perry C.M. Danaparoid, a review of its use in thromboembolic and coagulation disorders. Drugs 62 (2002) 2283-2314
43. Danhof M., De Boer A., Magnani H.N., et al. Pharmacokinetic considerations on orgaran (ORG-10172) therapy. Haemostasis 22 (1992) 73-84
44. Wilde M.I., and Markham A. Danaparoid, a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 54 (1997) 903-924
45. Product monograph Refludan, Berlex (Canada), preparation October 1999, revision April 2005
46. Chong B. Heparin-induced thrombocytopenia. J Thromb Haemostas 1 (2003) 1471-1478
47. Product monograph Angiomax, Oryx (Canada)
48. Product monograph Argatroban, Abbott Laboratories (USA), April 2003. Distributed by GlaxoSmithKline
49. Ferraris V.A., and Swanson E. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations. Surg Gynecol Obstet 156 (1983) 439-442
50. Scarborough R.M., Kleiman N.S., and Philips D.R. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?. Circulation 100 (1999) 437
51. Tcheng J.E. Clinical Challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy. bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 139 (2000) S38-S45
52. Nee R., Doppenschmidt D., Donovan D.J., et al. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol 83 (1999) 286-288
53. Ratnoff O.D. Some therapeutic agents influencing hemostasis. In: Colman R.W., Hirsh J., Marder V., et al. (Eds). Hemostasis and Thrombosis. ed 2 (1987), J.B. Lippincott Co, Philadelphia, PA 1026-1047
54. Park K.W. Protamine and protamine reactions. Int Anesthesiol Clin 42 (2004) 135-145
55. Crowther M.A., Berry L.R., Monagle P., et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116 (2002) 178-186
56. Bijsterveld N.R., Moons A.H., Boekholdt S.M., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106 (2002) 2550-2554
57. Nowak G., Bucha E., Goock T., et al. Pharmacology of r-hirudin in renal impairment. Thromb Res 66 (1992) 707-715
58. Horlocker T., Wedel D., Benzon H., et al. Regional anesthesia in the anticoagulated patient. defining the risks (The Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 28 (2003) 172-197